Jessica Douin, NP
Nurse Practitioner · Augusta, MENPI 1841745536
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $627 of the $943 with a category attached, or 66.5%. It is spread thinly across 15 manufacturers, the largest accounting for just 21.0%. 2025 is the largest year on record at $408, 8.2 times the $50 reported in 2021. Among nurse practitioner clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 21 payments — averaging $44.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$198
- AstraZeneca$154
- Astellas Pharma US Inc$134
- Daiichi Sankyo Inc.$112
- Johnson & Johnson$85
- GSK$51
- plus $209 from 9 others
What the payments were for
- Food & beverage$62767%
- Education$31633%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 2 | $198 |
| AstraZeneca | 5 | $154 |
| Astellas Pharma US Inc | 1 | $134 |
| Daiichi Sankyo Inc. | 1 | $112 |
| Johnson & Johnson | 1 | $85 |
| GSK | 2 | $51 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $33 |
| CTI Biopharma Corp. | 1 | $29 |
| AbbVie | 1 | $28 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Incyte Corporation | 1 | $22 |
| Morphosys, US Inc. | 1 | $21 |
| Novartis | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Bristol Myers Squibb | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PADCEV$134
How this compares
$943 in reported general payments places this provider in the 95th percentile of 740 nurse practitioner providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 28 | $614,691 |
| Lenalidomide | 27 | $393,908 |
| JakafiRuxolitinib Phosphate | 18 | $237,696 |
| IbrancePalbociclib | 14 | $221,488 |
| ErleadaApalutamide | 12 | $185,119 |
| Abiraterone Acetate | 75 | $128,466 |
| XermeloTelotristat Etiprate | 13 | $125,541 |
| CreonLipase/Protease/Amylase | 12 | $33,577 |
| EliquisApixaban | 18 | $10,279 |
| Ondansetron Hcl | 47 | $2,249 |
| Oxycodone Hcl | 59 | $1,712 |
| Anastrozole | 50 | $997 |
| Dexamethasone | 36 | $690 |
| Morphine Sulfate ErMorphine Sulfate | 18 | $610 |
| Acyclovir | 54 | $607 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $16 | $614,69128 claims |
| Incyte CorporationJakafi | $22 | $237,69618 claims |
| Johnson & JohnsonErleada | $85 | $185,11912 claims |
| AbbVieCreon | $28 | $33,57712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 740 nurse practitioner providers in Maine.
Other nurse practitioner in Augusta
- Jillian SavageAugusta$2K
- Ashley BrewAugusta$2K
- Margo TaylorAugusta$2K
- Andrea BerryAugusta$806
- Katie BesseyAugusta$750
- Cheryl SmithAugusta$733
- Katelyn IsaacAugusta$656
- Nicole LetendreAugusta$553
- Megan EvansAugusta$474
- Ginna DixAugusta$448
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.